ACIP Recommends RSV Vaccine

Following FDA’s May 2023 approval of Pfizer and GSK vaccines for respiratory syncytial virus (RSV), CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend that adults aged 60 and older may receive a single dose of the RSV vaccine, using shared clinical decision-making between the patient and their healthcare provider. Read more.